Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome
Received 13 November 2018
Accepted for publication 22 January 2019
Published 15 February 2019 Volume 2019:12 Pages 39—42
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Professor Ronald Prineas
Domenico Chirchiglia,1 Pasquale Chirchiglia,1 Rosa Marotta,2 Luca Gallelli3
1Department of Neurosurgery, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy; 2Department of Medical-Surgical Sciences, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy, 3Department of Pharmacology, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy
Aim: The purpose of this study was to treat burning mouth syndrome (BMS) with a combination of painful gabapentin and ultramicronized palmitoylethanolamide (umPEA), in an attempt to improve the severe symptomatology of BMS.
Methods: We examined the case of a 60-year-old male, suffering from late-onset burning mouth syndrome. He found that gabapentin had a poor control of symptoms, thus we added umPEA, after administering a Visual Analog Scale (VAS), showing a score of 8–9. The patient also underwent laboratory examinations, neuroimaging exams such as brain CT/MRI and others, which all showed normal results.
Results: The result of combined therapy was satisfactory. After 3 months, the frequency and intensity of the pain had improved considerably, as demonstrated clinically and by VAS, with a score of 5.
Conclusion: BMS is an oral pain-burning syndrome scarcely responsive to therapy. The most widely used medications are GABA-like substances, antidepressants, topiramate. In this case, we used PEA, which proved effective in the treatment of BMS, as well as in neuropathies and migraines.
Keywords: burning mouth syndrome, ultramicronized palmitoylethanolamide, gabapentin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]